drugset / Trial / NCT00143533
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
Phase 1
Completed
20 enrolled
St. Jude Children's Research Hospital
National Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to estimate the maximum tolerated dose of irinotecan with the use of cefpodoxime for pediatric solid tumor patients.
Timeline
- Start
- 2003-09
- Primary completion
- 2010-09
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefpodoxime | Small molecule | 10 mg/kg | Oral |
| Subject | Irinotecan | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 45 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 60 mg/m2 | Intravenous |